Body fat reduction

Body fat reduction is a physiological process and clinical endpoint characterized by the decrease of adipose tissue mass, typically occurring when energy expenditure exceeds caloric intake (NIH, 2023). It is not a specific molecular target (such as a receptor or enzyme) but rather a therapeutic goal or indication commonly targeted in the treatment of obesity and metabolic syndrome. Pharmacological interventions aiming to achieve body fat reduction operate by modulating distinct molecular targets, such as the Glucagon-like peptide 1 receptor (GLP-1R) to suppress appetite or the Melanocortin 4 receptor (MC4R) to regulate energy balance (PubMed, 2022). Clinically, the reduction of body fat—particularly visceral adiposity—is associated with significant improvements in insulin sensitivity, lipid profiles, and systemic inflammatory markers (StatPearls, 2023). In drug development, body fat reduction is often the primary efficacy endpoint in clinical trials for anti-obesity medications, measured through changes in total body weight or advanced imaging techniques like DXA scans.

Other names

Weight lossAdiposity reductionFat mass reductionLipid depletion

Body fat reduction is a physiological outcome achieved through multiple molecular mechanisms, including the activation of Glucagon-like peptide 1 receptors (GLP-1R) to induce satiety, inhibition of gastric and pancreatic lipases to prevent lipid absorption, and modulation of melanocortin receptors to increase energy expenditure.